原发性胆汁性胆管炎中的过氧化物酶体增殖物激活受体激动剂 - Suppr

Suppr

超能文献

PPAR Agonists in Primary Biliary Cholangitis.

作者信息

Schnabl Bernd

机构信息

From the Department of Medicine, University of California, San Diego, La Jolla.

出版信息

N Engl J Med. 2024 Feb 29;390(9):855-858. doi: 10.1056/NEJMe2313802. Epub 2024 Feb 21.

DOI:10.1056/NEJMe2313802

PMID:38381666

Abstract

摘要

相似文献

PPAR Agonists in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):855-858. doi: 10.1056/NEJMe2313802. Epub 2024 Feb 21.

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13.

Drugs targeting peroxisome proliferator-activated receptors.

Drug Discov Today. 2025 Mar;30(3):104318. doi: 10.1016/j.drudis.2025.104318. Epub 2025 Feb 20.

Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease.

Curr Opin Gastroenterol. 2025 Jul 1;41(4):281-288. doi: 10.1097/MOG.0000000000001109. Epub 2025 Jun 5.

Obeticholic acid (Ocaliva) for primary biliary cholangitis.

Med Lett Drugs Ther. 2017 Mar 27;59(1517):53-55.

Advancing Second-Line Treatment for Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):853-854. doi: 10.1056/NEJMe2312745. Epub 2024 Feb 21.

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis.

Expert Opin Pharmacother. 2024 Sep;25(13):1825-1834. doi: 10.1080/14656566.2024.2406268. Epub 2024 Oct 4.

PPAR agonists for primary biliary cholangitis.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):693-694. doi: 10.1016/S2468-1253(17)30256-X. Epub 2017 Aug 14.

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Front Immunol. 2022 Jul 8;13:940688. doi: 10.3389/fimmu.2022.940688. eCollection 2022.

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatol Commun. 2024 Dec 20;9(1). doi: 10.1097/HC9.0000000000000612. eCollection 2025 Jan 1.

引用本文的文献

A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.

Sci Rep. 2025 Apr 20;15(1):13645. doi: 10.1038/s41598-025-98200-y.

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatol Commun. 2024 Dec 20;9(1). doi: 10.1097/HC9.0000000000000612. eCollection 2025 Jan 1.

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment.

Clin Pharmacol Ther. 2025 Jan;117(1):240-249. doi: 10.1002/cpt.3450. Epub 2024 Oct 2.

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Cells. 2024 Sep 19;13(18):1580. doi: 10.3390/cells13181580.

Elafibranor: First Approval.

Drugs. 2024 Sep;84(9):1143-1148. doi: 10.1007/s40265-024-02075-8. Epub 2024 Aug 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

PPAR Agonists in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):855-858. doi: 10.1056/NEJMe2313802. Epub 2024 Feb 21.

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13.

Drugs targeting peroxisome proliferator-activated receptors.

Drug Discov Today. 2025 Mar;30(3):104318. doi: 10.1016/j.drudis.2025.104318. Epub 2025 Feb 20.

Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease.

Curr Opin Gastroenterol. 2025 Jul 1;41(4):281-288. doi: 10.1097/MOG.0000000000001109. Epub 2025 Jun 5.

Obeticholic acid (Ocaliva) for primary biliary cholangitis.

Med Lett Drugs Ther. 2017 Mar 27;59(1517):53-55.

Advancing Second-Line Treatment for Primary Biliary Cholangitis.

N Engl J Med. 2024 Feb 29;390(9):853-854. doi: 10.1056/NEJMe2312745. Epub 2024 Feb 21.

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis.

Expert Opin Pharmacother. 2024 Sep;25(13):1825-1834. doi: 10.1080/14656566.2024.2406268. Epub 2024 Oct 4.

PPAR agonists for primary biliary cholangitis.

Lancet Gastroenterol Hepatol. 2017 Oct;2(10):693-694. doi: 10.1016/S2468-1253(17)30256-X. Epub 2017 Aug 14.

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Front Immunol. 2022 Jul 8;13:940688. doi: 10.3389/fimmu.2022.940688. eCollection 2022.

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatol Commun. 2024 Dec 20;9(1). doi: 10.1097/HC9.0000000000000612. eCollection 2025 Jan 1.

引用本文的文献

A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model.

Sci Rep. 2025 Apr 20;15(1):13645. doi: 10.1038/s41598-025-98200-y.

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatol Commun. 2024 Dec 20;9(1). doi: 10.1097/HC9.0000000000000612. eCollection 2025 Jan 1.

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment.

Clin Pharmacol Ther. 2025 Jan;117(1):240-249. doi: 10.1002/cpt.3450. Epub 2024 Oct 2.

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Cells. 2024 Sep 19;13(18):1580. doi: 10.3390/cells13181580.

Elafibranor: First Approval.

Drugs. 2024 Sep;84(9):1143-1148. doi: 10.1007/s40265-024-02075-8. Epub 2024 Aug 7.